ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

[News]

ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

More... (http://www.news-medical.net/news/20100409/ZIOPHARM-Oncology-commences-Phase-III-study-of-Zybulin-for-metastatic-breast-cancer.aspx)